Novartis to spin off Alcon eye care unit, buy back $5B in stock; Rival CAR-Ts from Novartis and Gilead get thumbs up in Europe
→ Having mulled over it for more than a year, Novartis $NVS is finally spinning off Alcon, the eye care unit that former CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
